Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT05176002
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 35
- Registration Number
- NCT05171309
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2021-12-14
- Target Recruit Count
- 178
- Registration Number
- NCT05156970
- Locations
- 🇨🇳
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2021-12-09
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT05151549
Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 30
- Registration Number
- NCT05142865
- Locations
- 🇨🇳
Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
- Conditions
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Yue Han
- Target Recruit Count
- 48
- Registration Number
- NCT05135364
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 57
- Registration Number
- NCT05114707
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 65
- Registration Number
- NCT05111444
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 21
- Registration Number
- NCT05099848
- Locations
- 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China
Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 52
- Registration Number
- NCT05097248
- Locations
- 🇨🇳
Union Hospital, Tongji Medical College of HUST, Wuhan, Hubei, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.